Aisling Capital Overview

  • Investor Type
  • Venture Capital
  • Status
  • Active
  • Professionals
  • 10
Professionals
  • Investments
  • 223
  • Portfolio
  • 18
  • Exits
  • 150
Exits

Aisling Capital General Information

Description

Founded in 2000, Aisling Capital is a venture capital firm based in New York, New York. The firm prefers to invest in early-stage companies. The firm seeks to make investments in the technology, biopharma, consumer, diagnostics, medical device, service, and life-sciences sectors.

Contact Information

Formerly Known As
Perseus Soros Management
Year Founded
2000
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
PE/Buyout
Primary Office
  • 888 Seventh Avenue
  • 12th Floor
  • New York, NY 10106
  • United States
+1 (212) 000-0000

Aisling Capital Investments & Acquisitions (223)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Antios Therapeutics 12-Apr-2021 Early Stage VC 0000 Drug Discovery Clinical Trials - Phase 2
00000000 000000000 12-Apr-2021 00000 00000 00000 Biotechnology Stealth
00000 0000 0000000 21-Mar-2021 00000 00000 0000 Drug Discovery Generating Revenue/Not Profitable 000000 000000 00
00000 16-Mar-2021 00000 00000 000.00 Drug Discovery Generating Revenue/Not Profitable 000000 0000000
000000 000000 23-Dec-2020 00000 00000 0000 Drug Discovery Clinical Trials - Phase 1 0000 000000 00
000000000 00000000 12-Nov-2020 00000 00000 0000 Drug Discovery Clinical Trials - Phase 2
00000000 000 15-Oct-2020 00000 00000 00000 Drug Discovery Pre-Clinical Trials
0000000 0000000000 30-Sep-2020 00000 00000 00000 Biotechnology Clinical Trials - Phase 3
Monte Rosa Therapeutics 15-Sep-2020 Early Stage VC 0000 Drug Discovery Generating Revenue/Not Profitable 000000 000000 00
Spruce Biosciences 07-Aug-2020 Early Stage VC 0000 Drug Discovery Clinical Trials - Phase 2
You’re viewing 10 of 223 investments and acquisitions. Get the full list »
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aisling Capital Exits (150)

Company Name Exit Date Exit Type Exit Size
Talaris Therapeutics 07-May-2021 IPO 00000
000000 000000 16-Apr-2021 000 00000
00000 09-Apr-2021 000 000.00
0000000 24-Feb-2021 000000000000000000
00000000 000 10-Feb-2021 0000000 000000 00000
0000000 0000000000 13-Oct-2020 000000000000000000 00.00
000000 00000000000 09-Oct-2020 000 0000
0000000 0000000000 19-Aug-2020 000 00000
Poseida Therapeutics 10-Jul-2020 IPO 00000
EarLens 06-Apr-2020 Secondary Transaction - Private
You’re viewing 10 of 150 exits. Get the full list »

Aisling Capital Fund Performance

Fund Name Vintage Size Dry Powder DPI RVPI TVPI IRR

This information is available in the PitchBook Platform. To explore Aisling Capital‘s full profile, request access.

Request a free trial

Aisling Capital Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Aisling Capital Team (34)

Name Title Deals Funds Boards Office
Robert Wenzel Chief Financial Officer & Chief Compliance Officer, Legal New York, NY
Andrew Schiff MD Managing Partner 00 0 0 New York, NY
Steven Elms Managing Partner 00 0 0 New York, NY
Eric Aguiar MD Partner 00 0 0 New York, NY
Stacey Seltzer Partner 0 0 0 New York, NY
You’re viewing 5 of 34 team members. Get the full list »

Aisling Capital Co-Investors (139)

Name With Exits Lead Partner Series Industry
Cormorant Asset Management 8 0 0 Series chart Industry bar
Boxer Capital 0 0 0 Series chart Industry bar
Rock Springs Capital 0 0 0 Series chart Industry bar
Vivo Capital 0 0 0 Series chart Industry bar
HBM Healthcare Investments 0 0 0 Series chart Industry bar
You’re viewing 5 of 139 co-investors. Get the full list »